Related and unrelated nonmyeloablative hematopoietic stem cell transplantation for malignant diseases - PubMed (original) (raw)
Clinical Trial
. 2002 Aug:76 Suppl 1:184-9.
doi: 10.1007/BF03165242.
Michael Maris, Brenda M Sandmaier, David G Malone, Lyle Feinstein, Dietger Niederweiser, Judith A Shizuru, Peter A McSweeney, Thomas R Chauncey, Edward Agura, Marie-Trse Little, Firoozeh Sahebi, Ute Hegenbart, Michael A Pulsipher, Benedetto Bruno, Stephen Forman, Ann E Woolfrey, Jerald P Radich, Karl G Blume, Rainer Storb
Affiliations
- PMID: 12430851
- DOI: 10.1007/BF03165242
Clinical Trial
Related and unrelated nonmyeloablative hematopoietic stem cell transplantation for malignant diseases
George E Georges et al. Int J Hematol. 2002 Aug.
Abstract
Patients with advanced hematological malignancies ineligible for conventional myeloablative allogeneic hematopoietic stem cell transplantation (HSCT) due to advanced age or medical contraindications were enrolled in multi-center study to investigate the safety and efficacy of nonmyeloablative HSCT using a 2 Gy total body irradi ation (TBI)-based regimen. A total of 192 patients (median age 55) were treated with HLA-matched sibling peripheral blood stem cell (PBSC) grafts, and 63 patients (median age 53) received a 10 of 10 HLA-antigen matched unrelated donor (URD) HSCT (PBSC graft, n = 48; marrow graft, n = 15). Diagnoses included multiple myeloma (n = 61), myelodysplastic syndrome (n = 55), chronic myeloid leukemia (n = 31), non-Hodgkin lymphoma (n = 31), acute myeloid leukemia (n = 28), chronic lymphocytic leukemia (n = 24), Hodgkin Disease (n = 14). The conditioning regimen was fludarabine 30 mg/m2/d x 3 days and 2 Gy TBI. Ninety-five related HSCT patients received 2 Gy TBI without fludarabine. Postgrafting immunosuppression was combined mycophenolate mofetil an cyclosporine. Transplants were well tolerated with a median of 0 days of hospitalization in the first 60 days for eligible patients. For related HSCT recipients, median follow-up was 289 (100-1,188) days. Nonfatal graft rejection occurred in 6.8%. Of those with sustained engraftment, graft-versus-host disease (GVHD) occurred in 49% (33% grade II, 11% grade III, 5% grade IV). Day-100 non-relapse mortality was 6%. Overall, 59% (114/192) of patients were alive. The relapse/disease progression mortality was 18%, and non-relapse mortality was 22%. The projecte 2-year survival and progression-free survival were 50% and 40%. For the URD HSCT recipients, median follow-up was 190 (100-468) days. Graft rejection occurred in 27% (17/63) of patients, mostly in recipients of marrow grafts (9/15). Acute GVHD occurred in 63% (50% grade II, 13% grade III) of 46 engrafted patients. Chronic GVHD requiring therapy occurred in 50% of patients. Of the 63 URD HSCT patients, 54% were alive, 37% in CR, 3% PR, and 14% with disease progression or relapse. Related and unrelated nonmyeloablative HSCT is feasible and potentially curative in patients with advanced hematological malignancies who have no other treatment options.
Similar articles
- Low-dose total body irradiation, fludarabine, and antithymocyte globulin conditioning for nonmyeloablative allogeneic transplantation.
Grosskreutz C, Ross V, Scigliano E, Fruchtman S, Isola L. Grosskreutz C, et al. Biol Blood Marrow Transplant. 2003 Jul;9(7):453-9. doi: 10.1016/s1083-8791(03)00139-3. Biol Blood Marrow Transplant. 2003. PMID: 12869959 Clinical Trial. - Total Body Irradiation-Based Myeloablative Haploidentical Stem Cell Transplantation Is a Safe and Effective Alternative to Unrelated Donor Transplantation in Patients Without Matched Sibling Donors.
Solomon SR, Sizemore CA, Sanacore M, Zhang X, Brown S, Holland HK, Morris LE, Bashey A. Solomon SR, et al. Biol Blood Marrow Transplant. 2015 Jul;21(7):1299-307. doi: 10.1016/j.bbmt.2015.03.003. Epub 2015 Mar 19. Biol Blood Marrow Transplant. 2015. PMID: 25797174 Clinical Trial. - Cyclosporine and mycophenolate mofetil prophylaxis with fludarabine and melphalan conditioning for unrelated donor transplantation: a prospective study of 22 patients with hematologic malignancies.
Rodriguez R, Parker P, Nademanee A, Smith D, O'Donnell MR, Stein A, Snyder DS, Fung HC, Krishnan AY, Popplewell L, Cohen S, Somlo G, Angelopoulou M, Al-Kadhimi Z, Falk PM, Spielberger R, Kogut N, Sahebi F, Senitzer D, Slovak M, Schriber J, Forman SJ. Rodriguez R, et al. Bone Marrow Transplant. 2004 Jun;33(11):1123-9. doi: 10.1038/sj.bmt.1704493. Bone Marrow Transplant. 2004. PMID: 15064696 Clinical Trial. - Nonmyeloablative hematopoietic cell transplantation. Replacing high-dose cytotoxic therapy by the graft-versus-tumor effect.
Feinstein L, Sandmaier B, Maloney D, McSweeney PA, Maris M, Flowers C, Radich J, Little MT, Nash RA, Chauncey T, Woolfrey A, Georges G, Kiem HP, Zaucha JM, Blume KG, Shizuru J, Niederwieser D, Storb R. Feinstein L, et al. Ann N Y Acad Sci. 2001 Jun;938:328-37; discussion 337-9. Ann N Y Acad Sci. 2001. PMID: 11458521 Review.
Cited by
- HLA-mismatched unrelated donor transplantation using TLI-ATG conditioning has a low risk of GVHD and potent antitumor activity.
Spinner MA, Fernández-Viña M, Creary LE, Quinn O, Elder L, Arai S, Johnston LJ, Meyer EH, Miklos DB, Muffly LS, Negrin RS, Shizuru JA, Weng WK, Laport GG, Strober S, Lowsky R, Rezvani AR. Spinner MA, et al. Blood Adv. 2017 Jul 25;1(17):1347-1357. doi: 10.1182/bloodadvances.2017007716. eCollection 2017 Jul 25. Blood Adv. 2017. PMID: 29296777 Free PMC article. - Association between genetic variants in adhesion molecules and outcomes after hematopoietic cell transplants.
Thyagarajan B, Jackson S, Basu S, Jacobson P, Gross MD, Weisdorf DJ, Arora M. Thyagarajan B, et al. Int J Immunogenet. 2013 Apr;40(2):108-15. doi: 10.1111/j.1744-313X.2012.01131.x. Epub 2012 May 30. Int J Immunogenet. 2013. PMID: 22646485 Free PMC article. - NKT cells, Treg, and their interactions in bone marrow transplantation.
Kohrt HE, Pillai AB, Lowsky R, Strober S. Kohrt HE, et al. Eur J Immunol. 2010 Jul;40(7):1862-9. doi: 10.1002/eji.201040394. Eur J Immunol. 2010. PMID: 20583031 Free PMC article. Review. - TLI and ATG conditioning with low risk of graft-versus-host disease retains antitumor reactions after allogeneic hematopoietic cell transplantation from related and unrelated donors.
Kohrt HE, Turnbull BB, Heydari K, Shizuru JA, Laport GG, Miklos DB, Johnston LJ, Arai S, Weng WK, Hoppe RT, Lavori PW, Blume KG, Negrin RS, Strober S, Lowsky R. Kohrt HE, et al. Blood. 2009 Jul 30;114(5):1099-109. doi: 10.1182/blood-2009-03-211441. Epub 2009 May 7. Blood. 2009. PMID: 19423725 Free PMC article. Clinical Trial. - Assessment of the hematopoietic cell transplantation comorbidity index in non-Hodgkin lymphoma patients receiving reduced-intensity allogeneic hematopoietic stem cell transplantation.
Pollack SM, Steinberg SM, Odom J, Dean RM, Fowler DH, Bishop MR. Pollack SM, et al. Biol Blood Marrow Transplant. 2009 Feb;15(2):223-30. doi: 10.1016/j.bbmt.2008.11.023. Biol Blood Marrow Transplant. 2009. PMID: 19167682 Free PMC article.
References
- N Engl J Med. 1975 Apr 17;292(16):832-43 - PubMed
- N Engl J Med. 1979 May 10;300(19):1068-73 - PubMed
- Cancer Res. 1965 Oct;25(9):1525-31 - PubMed
- Blood. 1997 Apr 15;89(8):3048-54 - PubMed
- Blood. 2001 Dec 15;98(13):3584-8 - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- CA78902/CA/NCI NIH HHS/United States
- CA18221/CA/NCI NIH HHS/United States
- HL 36444/HL/NHLBI NIH HHS/United States
- CA15704/CA/NCI NIH HHS/United States
- DK42716/DK/NIDDK NIH HHS/United States
- P01 CA078902/CA/NCI NIH HHS/United States
LinkOut - more resources
Research Materials